Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.3.0.814
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 13,709 $ 8,391
Marketable securities, current 42,705 50,209
Collaboration receivable 4,032 7,248
Prepaid expenses and other current assets 1,785 832
Total current assets 62,231 66,680
Property and equipment, net 404 557
Other assets 1,329 1,159
Total assets 63,964 68,396
Current liabilities:    
Accounts payable 436 2,074
Accrued clinical and development expenses 5,898 5,998
Accrued liabilities 3,202 3,180
Deferred revenue, current 14,722 14,722
Total current liabilities 24,258 25,974
Warrant liability 19,295 3,961
Deferred revenue, non-current 51,153 62,194
Deferred rent 153 243
Total liabilities $ 94,859 $ 92,372
Commitments and contingencies (Note 7)
Stockholders’ equity (deficit):    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 71,431,059 shares at September 30, 2015 and 62,898,233 shares at December 31, 2014 $ 71 $ 63
Additional paid-in capital 368,190 349,236
Accumulated other comprehensive loss (3) (13)
Accumulated deficit (399,153) (373,262)
Total stockholders’ equity (deficit) (30,895) (23,976)
Total liabilities and stockholders’ equity (deficit) $ 63,964 $ 68,396